Cerus Corp. [CERS] stock prices are up 6.82% to $1.88 at the moment. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The CERS shares have gain 8.05% over the last week, with a monthly amount drifted -11.32%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
On 26, March 2024, Cerus Corporation Announces FDA Approval of Extended Shelf Life for INTERCEPT Platelet Processing Sets – Doubling Previous Shelf Life. In a post published today on Yahoo Finance, Cerus Corporation (Nasdaq: CERS) today announced that the U.S. Food and Drug Administration (FDA) has granted approval of 12-month shelf life for INTERCEPT Platelet Processing Sets, from the date of manufacture, effective immediately. This approval extends the set shelf life by six months from the existing six-month shelf life that took effect following a set component change last year. All INTERCEPT Platelet Processing Sets in both customer and Cerus inventories are now eligible for this six-month extension. This shelf-life extension applies to all sizes of INTERCEPT Platelet Processing Sets currently available in the U.S.
From an analyst’s perspective:
Cerus Corp. [NASDAQ: CERS] stock has seen the most recent analyst activity on January 20, 2023, when BTIG Research downgraded its rating to a Neutral. Previously, Stephens downgraded its rating to Equal-Weight on January 17, 2023, and kept the price target unchanged to $3.75. BTIG Research initiated its recommendation with a Buy and recommended $7 as its price target on February 26, 2020. BTIG Research upgraded its rating to Buy for this stock on November 13, 2019, but kept the price target unchanged to $7. In a note dated August 28, 2019, Stifel initiated an Buy rating.
The stock price of Cerus Corp. [CERS] has been fluctuating between $1.21 and $3.08 over the past year. Cerus Corp. [NASDAQ: CERS] shares were valued at $1.88 at the most recent close of the market.
Analyzing the CERS fundamentals
The Cerus Corp. [NASDAQ:CERS] reported sales of 156.37M for trailing twelve months, representing a surge of 6.21%. Gross Profit Margin for this corporation currently stands at 0.55% with Operating Profit Margin at -0.23%, Pretax Profit Margin comes in at -0.24%, and Net Profit Margin reading is -0.24%. To continue investigating profitability, this company’s Return on Assets is posted at -0.19, Equity is -0.71 and Total Capital is -0.28. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of1.56.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 1.7700 points at the first support level, and at 1.6600 for the second support level. However, for the 1st resistance point, the stock is sitting at 1.9400, and for the 2nd resistance point, it is at 2.0000.
Cerus Corp. [CERS] reported earnings per share of -$0.01 for its fiscal quarter that ended on 12/30/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$0.02/share, meaning a difference of $0.01 and a surprise factor of 50.00%. By comparison, the stated earnings for the previous quarter ended on 9/29/2023 were -$0.04 per share as compared to estimates of -$0.05 per share, a difference of $0.01 representing a surprise of 20.00%.
Ratios To Look Out For
It’s worth pointing out that Cerus Corp. [NASDAQ:CERS]’s Current Ratio is 2.14. Also, the Quick Ratio is 1.55, while the Cash Ratio stands at 0.17. Considering the valuation of this stock, the price to sales ratio is 2.18, the price to book ratio is 6.47.
Transactions by insiders
Recent insider trading involved Greenman William Mariner, President and CEO, that happened on Mar 14 ’24 when 63611.0 shares were sold. Chief Operating Officer, Jayaraman Vivek K completed a deal on Mar 14 ’24 to sell 26794.0 shares. Meanwhile, Chief Financial Officer Green Kevin Dennis sold 21497.0 shares on Mar 14 ’24.
